Biomerica, Inc. BMRA
NASDAQ
| 08/31/2026 | 05/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 44.57% | -11.35% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 44.57% | -11.35% | |||
| Cost of Revenue | 22.83% | -8.24% | |||
| Gross Profit | 245.07% | -61.36% | |||
| SG&A Expenses | -10.58% | 16.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.49% | 5.38% | |||
| Operating Income | 19.96% | -18.10% | |||
| Income Before Tax | -7.64% | 12.65% | |||
| Income Tax Expenses | 0.00% | -25.00% | |||
| Earnings from Continuing Operations | -7.60% | 12.73% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.60% | 12.73% | |||
| EBIT | 19.96% | -18.10% | |||
| EBITDA | 20.05% | -18.62% | |||
| EPS Basic | -1.33% | 15.35% | |||
| Normalized Basic EPS | 55.14% | -91.47% | |||
| EPS Diluted | 0.45% | 14.66% | |||
| Normalized Diluted EPS | 55.14% | -91.47% | |||
| Average Basic Shares Outstanding | 6.20% | 3.10% | |||
| Average Diluted Shares Outstanding | 6.20% | 3.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||